ClinicalTrials.Veeva

Menu
R

Retina Research Institute of Texas | Abilene, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KSI-301
Aflibercept
APL-2
Sunitinib Malate
Abicipar Pegol
KHK4951
Ranibizumab
THR-149
GB-102
IONIS-FB-LRx

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 67 total trials

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability an...

Begins enrollment this month
Neovascular Age-related Macular Degeneration (nAMD)
Drug: RBS-001 Solution for intravitreal injection
Drug: Eylea® Solution for intravitreal injection

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling
Diabetic Macular Edema (DME)
Drug: EYE103
Drug: Ranibizumab

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (...

Enrolling
Wet Age-related Macular Degeneration
Drug: Tarcocimab tedromer
Drug: Aflibercept

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate 4 dosing cohorts of AG-73305 administered by intravitreal inje...

Active, not recruiting
Diabetic Macular Edema
Drug: AG-73305

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), in...

Enrolling
Neovascular (Wet) AMD
Drug: ABI-110 High Dose
Drug: ABI-110 Low Dose

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Enrolling
Age Related Macular Degeneration (ARMD)
Drug: Elamipretide
Drug: Placebo

Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-1...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Drug: OCU-10-C-110 for Injection

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Drug: AR-14034 SR implant lower dose
Drug: AR-14034 SR implant higher dose
Locations recently updated

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Enrolling
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of supr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: Aflibercept
Drug: CLS-AX
Recently updated

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Enrolling
Uveitic Macular Edema
Other: Sham
Drug: Vamikibart

Trial sponsors

Kodiak Sciences logo
Allergan logo
A
C
AbbVie logo
Boehringer Ingelheim logo
E
E
G
Kyowa Kirin logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems